GrayMatters Health Co-founders CEO and President Oded Kraft and VP R&D Shai Attia are both Technion alumni
A study by GrayMatters Health, which develops digital training therapies to help the brain regulate mental health care, has shown that its FDA-approved Prism device is effective in the treatment of post-traumatic stress disorder (PTSD).
The device, now available in selected clinics in the US, shows a patient’s brain activity in the amygdala, the small region of the brain associated with emotions and memory, while interacting with different scenarios.
This can help patients with PTSD control their symptoms by better understanding what triggers that heightened activity in that part of the brain.
The study included 79 male and female patients, including combat veterans with chronic PTSD. It checked each patient’s Clinician-Administered PTSD Scale (CAPS-5), a diagnostic interview that gives a patient a medical diagnosis and a symptom severity rating.
According to the study, which was published in the Journal of Psychiatry Research, 32 percent of patients achieved remission after three months of using the device.
“Millions of Americans struggling with PTSD must navigate medication side effects, revisit traumatic experiences with psychotherapy or choose not to seek treatment due to societal stigma,” said Oded Kraft, CEO and co-founder of Haifa-based GrayMatters Health.
“These clinical results build on prior research and demonstrate that Prism offers patients living with PTSD an effective and safe pathway toward improved mental health,” he said.